CA2747955C - Implantable devices for treating hiv - Google Patents

Implantable devices for treating hiv Download PDF

Info

Publication number
CA2747955C
CA2747955C CA2747955A CA2747955A CA2747955C CA 2747955 C CA2747955 C CA 2747955C CA 2747955 A CA2747955 A CA 2747955A CA 2747955 A CA2747955 A CA 2747955A CA 2747955 C CA2747955 C CA 2747955C
Authority
CA
Canada
Prior art keywords
tmc278
implantable
samples
weight
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2747955A
Other languages
English (en)
French (fr)
Other versions
CA2747955A1 (en
Inventor
Deborah M. Schachter
Qiang Zhang
Lieven Elvire Colette Baert
Han Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of CA2747955A1 publication Critical patent/CA2747955A1/en
Application granted granted Critical
Publication of CA2747955C publication Critical patent/CA2747955C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
CA2747955A 2008-12-24 2009-12-24 Implantable devices for treating hiv Active CA2747955C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14069408P 2008-12-24 2008-12-24
US61/140,694 2008-12-24
PCT/EP2009/067933 WO2010072844A1 (en) 2008-12-24 2009-12-24 Implantable devices for treating hiv

Publications (2)

Publication Number Publication Date
CA2747955A1 CA2747955A1 (en) 2010-07-01
CA2747955C true CA2747955C (en) 2017-06-13

Family

ID=42167643

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2747955A Active CA2747955C (en) 2008-12-24 2009-12-24 Implantable devices for treating hiv

Country Status (18)

Country Link
US (3) US20110256206A1 (de)
EP (1) EP2381961B1 (de)
JP (1) JP5612602B2 (de)
KR (1) KR101726615B1 (de)
CN (1) CN102711834B (de)
AU (1) AU2009332910B2 (de)
BR (1) BRPI0923161B1 (de)
CA (1) CA2747955C (de)
ES (1) ES2607107T3 (de)
HK (1) HK1172842A1 (de)
IL (1) IL213542A (de)
MX (1) MX2011006856A (de)
MY (1) MY160360A (de)
NZ (1) NZ593950A (de)
RU (1) RU2546529C2 (de)
SG (2) SG196774A1 (de)
WO (1) WO2010072844A1 (de)
ZA (1) ZA201104669B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181759A1 (en) 2009-12-21 2012-07-30 Janssen R & D Ireland Degradable removable implant for the sustained release of an active compound
US20130341811A1 (en) * 2012-06-25 2013-12-26 Johnson & Johnson Vision Care, Inc. Lens comprising low and high molecular weight polyamides
US9423528B2 (en) 2012-06-25 2016-08-23 Johnson & Johnson Vision Care, Inc. Method of making silicone containing contact lens with reduced amount of diluents
JP6835841B2 (ja) * 2015-11-16 2021-02-24 エボニック オペレーションズ ゲーエムベーハー 非核酸系逆転写酵素阻害剤とポリ（ラクチド−ｃｏ−グリコリド）とを含む注射液
US11400186B2 (en) * 2016-05-12 2022-08-02 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
EP1309904A4 (de) * 2000-03-03 2006-03-29 Valentis Inc Verbesserte poloxamer- und polyoaminverbindungen zur nukleinsäureeinbringung
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US7201925B2 (en) * 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
US20060034797A1 (en) 2002-05-03 2006-02-16 Arien Albertina M E Polymeric micromulsions
WO2005067889A1 (en) * 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
RS53890B1 (en) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. STABILIZED POLYMER DELIVERY SYSTEM
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
EP1893180A2 (de) * 2005-06-07 2008-03-05 Pfizer Products Inc. Multipartikeln mit schwer löslichen arzneimitteln und eine schnelle arzneimittelfreisetzung ergebende träger
PL1981506T6 (pl) * 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
CA2654115C (en) * 2006-06-23 2015-12-22 Tibotec Pharmaceuticals Ltd. Aqueous suspensions of tmc278

Also Published As

Publication number Publication date
KR101726615B1 (ko) 2017-04-13
IL213542A (en) 2017-02-28
MY160360A (en) 2017-02-28
HK1172842A1 (zh) 2013-05-03
NZ593950A (en) 2013-08-30
EP2381961B1 (de) 2016-09-14
BRPI0923161A2 (pt) 2016-02-10
RU2011130557A (ru) 2013-01-27
CA2747955A1 (en) 2010-07-01
SG172398A1 (en) 2011-07-28
KR20110117100A (ko) 2011-10-26
JP2012513969A (ja) 2012-06-21
ZA201104669B (en) 2018-11-28
ES2607107T3 (es) 2017-03-29
SG196774A1 (en) 2014-02-13
IL213542A0 (en) 2011-07-31
AU2009332910B2 (en) 2015-10-15
MX2011006856A (es) 2011-08-03
US20220079875A1 (en) 2022-03-17
AU2009332910A1 (en) 2011-07-07
EP2381961A1 (de) 2011-11-02
BRPI0923161B1 (pt) 2019-01-15
WO2010072844A1 (en) 2010-07-01
US20180235872A1 (en) 2018-08-23
US20110256206A1 (en) 2011-10-20
CN102711834A (zh) 2012-10-03
JP5612602B2 (ja) 2014-10-22
RU2546529C2 (ru) 2015-04-10
CN102711834B (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
US20220079875A1 (en) Implantable devices for treating hiv
EP2575890B1 (de) Antipsychotikum in form einer injizierbaren depotzusammensetzung
EP3643298A1 (de) In-situ-phasenwechselgel mit verzögerter freisetzung für niedermolekulare arzneimittel und herstellungsverfahren dafür
AU2018229750B2 (en) Pharmaceutical composition comprising selexipag
KR102272235B1 (ko) 항바이러스제의 전달을 위한 약물 전달 시스템
US20220072134A1 (en) Temperature-responsive degradable hydrogels
WO2017222903A1 (en) Drug delivery system for the delivery of antiviral agents
DK2485717T3 (en) Continuous release delivery system for a calcium channel blocking agent
EP3700589A1 (de) Temperaturreaktive abbaubare hydrogele
WO1999051201A1 (en) Sustained release formulation
AU2015250470A1 (en) Active ingredient (I) containing composition and method for preparing same
Sali et al. A Review on: Atrigel-The Magical Tool
CN106236698A (zh) 一种胍法辛植入剂及制备方法
Copeland Optimization of an in situ forming implant system for long-acting Human Immunodeficiency Virus (HIV) Prevention
JPWO2015133580A1 (ja) 注入可能なポリ乳酸類含有組成物
WO2023183799A1 (en) Biodegradable controlled release antiviral agent implants
AU3176999A (en) Sustained release formulation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141222